Director
DIN: 06415261
Vishwajeet Ankush Gaikwad is currently associated with 2 companies in various capacities such as Managing Director and Individual Promoter. They serve as a Director at HUMANKIND PHARMA PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 06415261.Vishwajeet Ankush Gaikwad has previously been associated with 1 company in roles such as Director.Vishwajeet Ankush Gaikwad is currently involved in 2 different roles. Their most recent position is with MEDOCARE INDIA PRIVATE LIMITED as a Individual Promoter. The first company Vishwajeet Ankush Gaikwad was appointed to was HUMANKIND PHARMA PRIVATE LIMITED. Vishwajeet Ankush Gaikwad has a status of Deactivated. Please verify the details for any specific requirements or conditions.
Vishwajeet Ankush Gaikwad is currently associated with 2 companies in various capacities such as Managing Director and Individual Promoter. They serve as a Director at HUMANKIND PHARMA PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 06415261.Vishwajeet Ankush Gaikwad has previously been associated with 1 company in roles such as Director.Vishwajeet Ankush Gaikwad is currently involved in 2 different roles. Their most recent position is with MEDOCARE INDIA PRIVATE LIMITED as a Individual Promoter. The first company Vishwajeet Ankush Gaikwad was appointed to was HUMANKIND PHARMA PRIVATE LIMITED. Vishwajeet Ankush Gaikwad has a status of Deactivated. Please verify the details for any specific requirements or conditions.
2
Male
India
Call +91 81049 46419 and we'll pull the verified contact details for you.
Current Companies (2)
Current LLPs (0)
Past Companies (1)
2y 9m 1y 5m Interval
| Company Name | Designation | Date of Appointment |
|---|---|---|
| HUMANKIND PHARMA PRIVATE LIMITED | Managing Director | 15-Jan-2013 |
| MEDOCARE INDIA PRIVATE LIMITED | Individual Promoter | 08-Sep-2016 |